Yaron Werber
Stock Analyst at TD Cowen
(0.86)
# 3,668
Out of 4,732 analysts
40
Total ratings
29.63%
Success rate
-19.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yaron Werber
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Initiates: Buy | n/a | $20.00 | - | 1 | Dec 20, 2024 | |
| SEPN Septerna | Initiates: Buy | n/a | $16.89 | - | 1 | Nov 19, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $160 → $153 | $128.13 | +19.41% | 5 | Nov 15, 2024 | |
| BNTX BioNTech SE | Maintains: Hold | $132 → $122 | $111.93 | +9.00% | 5 | Nov 6, 2024 | |
| UPB Upstream Bio | Initiates: Buy | n/a | $11.00 | - | 1 | Nov 5, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $61 → $73 | $40.00 | +82.50% | 2 | Oct 21, 2024 | |
| EXEL Exelixis | Maintains: Buy | $27 → $34 | $36.20 | -6.08% | 2 | Oct 21, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $54 → $59 | $31.43 | +87.72% | 1 | Jul 23, 2024 | |
| LEGN Legend Biotech | Maintains: Buy | $71 → $67 | $32.66 | +105.14% | 2 | Jul 15, 2024 | |
| STOK Stoke Therapeutics | Upgrades: Buy | n/a | $9.36 | - | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.51 | - | 1 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.02 | - | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.61 | - | 2 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $23.78 | - | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $612 → $641 | $640.52 | +0.07% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.95 | - | 1 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $25 | $0.57 | +4,264.53% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $20.97 | - | 2 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $38 | $20.80 | +82.69% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.35 | - | 3 | Apr 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.84 | - | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.15 | - | 1 | Oct 26, 2021 |
Dianthus Therapeutics
Dec 20, 2024
Initiates: Buy
Price Target: n/a
Current: $20.00
Upside: -
Septerna
Nov 19, 2024
Initiates: Buy
Price Target: n/a
Current: $16.89
Upside: -
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $160 → $153
Current: $128.13
Upside: +19.41%
BioNTech SE
Nov 6, 2024
Maintains: Hold
Price Target: $132 → $122
Current: $111.93
Upside: +9.00%
Upstream Bio
Nov 5, 2024
Initiates: Buy
Price Target: n/a
Current: $11.00
Upside: -
Ultragenyx Pharmaceutical
Oct 21, 2024
Maintains: Buy
Price Target: $61 → $73
Current: $40.00
Upside: +82.50%
Exelixis
Oct 21, 2024
Maintains: Buy
Price Target: $27 → $34
Current: $36.20
Upside: -6.08%
Ionis Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $54 → $59
Current: $31.43
Upside: +87.72%
Legend Biotech
Jul 15, 2024
Maintains: Buy
Price Target: $71 → $67
Current: $32.66
Upside: +105.14%
Stoke Therapeutics
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $9.36
Upside: -
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $5.51
Upside: -
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.02
Upside: -
Jan 31, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.61
Upside: -
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $23.78
Upside: -
Dec 12, 2023
Maintains: Outperform
Price Target: $612 → $641
Current: $640.52
Upside: +0.07%
Oct 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.95
Upside: -
Feb 28, 2023
Maintains: Market Perform
Price Target: $15 → $25
Current: $0.57
Upside: +4,264.53%
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $20.97
Upside: -
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $20.80
Upside: +82.69%
Apr 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $8.35
Upside: -
Nov 30, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.84
Upside: -
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.15
Upside: -